COMP <GO>
CI vs LLY // ALTMAN Z-SCORE & DEBT/EQUITY
The Cigna Group (NYSE) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: CI 4
— LLY 10
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: LLY
LAST: $298.41 (+1.16%) • MKT CAP: $78.85B
balance-sheet
2.70
LAST: $1,373.70 (+6.63%) • MKT CAP: $1.29T
balance-sheet
9.29
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CI VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CI | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 21.80% | 83.64% | -61.84 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 8.80% | 32.36% | -23.56 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 6.1x | 36.4x | -30.32 | CI | /valuation <GO> |
| Free Cash Flow Yield | -3.51% | 2.30% | -5.81 | LLY | /fcf-yield <GO> |
| Operating Margin | 3.30% | 40.21% | -36.91 | LLY | /operating-margins <GO> |
| Net Profit Margin | 2.20% | 31.90% | -29.70 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 11.20% | 45.51% | -34.31 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 2.04% | 0.49% | +1.55 | CI | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 2.70 | 9.29 | -6.59 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 9/9 | -4.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.77% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 55.8 | 66.6 | -10.80 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.12 | 0.51 | +0.61 | CI | /macro-sensitivity <GO> |
| Forward P/E Multiple | 12.3x | 26.3x | -13.95 | CI | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $78.85B | $1.29T | -$1.21T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CI REV | LLY REV | CI GROSS % | LLY GROSS % | CI FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $274.90B | $65.18B | 21.8% | 83.0% | -$2.77B | $16.81B |
| FY 2024 | $247.12B | $45.04B | 26.1% | 81.3% | -$757.4M | $8.82B |
| FY 2023 | $195.26B | $34.12B | — | 79.3% | $3.03B | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CI // BETA 1.12
LLY // BETA 0.51